142 related articles for article (PubMed ID: 4853286)
1. Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure.
Sadée W; Schröder R; von Leitner E; Dagcioglu M
Eur J Clin Pharmacol; 1974; 7(3):195-200. PubMed ID: 4853286
[No Abstract] [Full Text] [Related]
2. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.
Sadée W; Dagcioglu M; Schröder R
J Pharmacol Exp Ther; 1973 Jun; 185(3):686-95. PubMed ID: 4712657
[No Abstract] [Full Text] [Related]
3. Canrenoate in normal man.
Mroczek WJ; Davidov ME; Horoschak A; Finnerty FA
Clin Pharmacol Ther; 1974 Aug; 16(2):336-42. PubMed ID: 4368469
[No Abstract] [Full Text] [Related]
4. Elimination of canrenone in congestive heart failure and chronic liver disease.
Jackson L; Branch R; Levine D; Ramsay L
Eur J Clin Pharmacol; 1977 Mar; 11(3):177-9. PubMed ID: 852495
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of spironolactone after a single dose: evaluation of the true canrenone serum concentrations during 24 hours.
Merkus FW; Overdiek JW; Cilissen J; Zuidema J
Clin Exp Hypertens A; 1983; 5(2):239-48. PubMed ID: 6831747
[No Abstract] [Full Text] [Related]
6. Conversion of spironolactone to canrenone and disposition kinetics of spironolactone and canrenoate-potassium in rats.
Sadée W; Abshagen U; Finn C; Rietbrock N
Naunyn Schmiedebergs Arch Pharmacol; 1974; 283(3):303-18. PubMed ID: 4276758
[No Abstract] [Full Text] [Related]
7. [Aldosterone antagonists in coronary insufficiency].
Osswald H
Med Klin; 1978 Jan; 73(3):84-8. PubMed ID: 622061
[No Abstract] [Full Text] [Related]
8. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
Andriulli A; Arrigoni A; Gindro T; Karbowiak I; Buzzetti G; Armanini D
Digestion; 1989; 44(3):155-62. PubMed ID: 2697627
[TBL] [Abstract][Full Text] [Related]
9. Comparative clinical study of spironolactone and potassium canrenoate. A randomized evaluation with double cross-over.
Emili M; Cuppone R; Ricci GL
Arzneimittelforschung; 1988 Oct; 38(10):1492-5. PubMed ID: 3058132
[TBL] [Abstract][Full Text] [Related]
10. Spironolactone metabolism in normal subjects and in patients with liver cirrhosis.
Váradi A; Fehér T; Bodrogi L; Koref O
Arzneimittelforschung; 1977; 27(8):1618-20. PubMed ID: 578759
[TBL] [Abstract][Full Text] [Related]
11. [Effect of spironolactone and K-canrenoate in ascitic cirrhosis. Double-blind study].
Tempini S; Bellati G; Ideo G
Minerva Dietol Gastroenterol; 1984; 30(3):255-61. PubMed ID: 6504374
[No Abstract] [Full Text] [Related]
12. Pharmacokinetics of spironolactone and potassium canrenoate in humans.
Kojima K; Yamamoto K; Fujioka H; Kaneko H
J Pharmacobiodyn; 1985 Mar; 8(3):161-6. PubMed ID: 4009408
[TBL] [Abstract][Full Text] [Related]
13. Canrenoate--a spironolactone metabolite. Acute cardiac effects in digitalized patients.
Waldorff S; Buch J
Eur J Cardiol; 1979 Aug; 10(2):143-9. PubMed ID: 477703
[TBL] [Abstract][Full Text] [Related]
14. Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels.
Karim A; Zagarella J; Hutsell TC; Dooley M
Clin Pharmacol Ther; 1976 Feb; 19(2):177-82. PubMed ID: 1261155
[TBL] [Abstract][Full Text] [Related]
15. Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment.
Abshagen U; Rennekamp H; Luszpinski G
Eur J Clin Pharmacol; 1977 Mar; 11(3):169-76. PubMed ID: 856602
[TBL] [Abstract][Full Text] [Related]
16. Enhancement by food of canrenone bioavailability from spironolactone.
Melander A; Danielson K; Scherstén B; Thulin T; Wåhlin E
Clin Pharmacol Ther; 1977 Jul; 22(1):100-3. PubMed ID: 872489
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of aldosterone production in diuretic-induced hyperaldosteronism by aldosterone antagonist canrenone in man.
Erbler HC
Naunyn Schmiedebergs Arch Pharmacol; 1974; 285(4):395-401. PubMed ID: 4280522
[No Abstract] [Full Text] [Related]
18. Cerebral uptake of a 3 H-labelled spirolactone compound in the dog.
Schmiedek P; Sadée W; Baethmann A
Eur J Pharmacol; 1973 Feb; 21(2):238-41. PubMed ID: 4696105
[No Abstract] [Full Text] [Related]
19. Spironolactone and canrenoate-K: relative potency at steady state.
Ramsay L; Asbury M; Shelton J; Harrison I
Clin Pharmacol Ther; 1977 May; 21(5):602-9. PubMed ID: 858213
[TBL] [Abstract][Full Text] [Related]
20. Effect of spironolactone and potassium canrenoate on cytosolic and nuclear androgen and estrogen receptors of rat liver.
Francavilla A; Di Leo A; Eagon PK; Polimeno L; Guglielmi F; Fanizza G; Barone M; Starzl TE
Gastroenterology; 1987 Oct; 93(4):681-6. PubMed ID: 3623016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
